39 results about "Alpha-fetoprotein" patented technology

The invention provides a detection method of an end face integrated reflection type SPR optical fiber biosensor manufactured based on a 2PP technology. An experiment system mainly comprises a single-mode optical fiber, an optical fiber coupler, an SPR probe, a tungsten lamp light source, a sample pool, a spectrum analyzer and a computer. The method is characterized in that a volcanic three-dimensional microstructure is directly constructed on the end face of a single-mode fiber through a 2PP technology, a metal film with the thickness of about 50nm is deposited on the inner wall of the volcanic three-dimensional microstructure, and a stable and efficient SPR excitation structure is formed; the structural parameters are subjected to FDTD simulation optimization design, and have the characteristics of high quality factor and high sensitivity. The sensor can be used for AFP detection, the sensitivity reaches 0.684 nm / (ng / mL) within the linear range of 0-10 ng / mL, the normal and risk early warning concentration interval of human serum AFP is covered, and the sensor has good biological suitability and early hepatocellular carcinoma screening capacity; in addition, the probe structure is small in size, detection can be completed only by a few microliters of liquid to be detected, and the probe is suitable for a microfluidic platform with an extremely low sample size or a clinical sampling scene. Compared with the prior art, the device has the advantages of high structural integration, high sensitivity, low sample consumption, convenience in manufacturing, stability, reliability and the like.

The invention belongs to the technical field of optical fiber sensing, and provides an optical fiber microstructure biosensor for detecting alpha fetoprotein and a preparation method thereof, and the method comprises the following steps: step 1, synthesizing a gold nanorod; 2, selecting a single-mode optical fiber for real-time monitoring, removing a coating layer, placing the single-mode optical fiber in a fusion splicer, drawing to obtain a micro-conical optical fiber, enabling CO2 laser to act on a conical waist area of the micro-conical optical fiber to manufacture a cone, taking out the optical fiber, and cooling and curing to obtain an optical fiber microstructure sensor; step 3, immersing a sensing area of the optical fiber microstructure sensor into NaOH, washing and drying, and immersing the sensing area into an MPTMS-ethanol solution; washing is carried out, and then the sensing area is immersed in a GNRs-PEG-COOH solution; washing and drying, immersing the sensing area in an EDC / NHS mixed solution for soaking, washing and drying, and putting the sensing area in an mAb solution for soaking; and washing and drying to obtain the optical fiber microstructure biosensor.

The invention relates to the technical field of biological medicine, in particular to a T cell receptor targeting AFP peptide, a preparation method of the T cell receptor and a companion diagnostic kit. A T cell receptor targeting an AFP peptide is provided, the sequence of the AFP peptide is FMNKFIYEI, and the T cell receptor comprises a TCR [alpha] chain variable domain and a TCR [beta] chain variable domain. Corresponding nucleic acid molecules, vectors and host cells, and methods of making T cell receptors are provided. Further provided is a companion diagnostic kit containing the cell receptor. The invention provides a better choice for concomitant diagnosis and treatment products of cells of alpha fetoprotein (AFP).

The invention belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of treating hepatocellular carcinoma by combining TACE with Czodili monoclonal antibody and bevacizumab, and a construction method and application of an FAAP prognostic scoring model. The invention develops and verifies an FAAP prognostic scoring system, and a novel composite model integrates four indexes of fibrin degradation product / cholinesterase ratio * 1000 (FCR), aspartate aminotransferase (AST), alpha fetoprotein (AFP) and portal vein tumor thrombus (PVTT), and is used for predicting the survival condition of uHCC patients subjected to TACE-Czodimab-bevacizumab triple therapy. The tool has an instant clinical value, can optimize patient selection, guides adaptive treatment upgrading, and provides a standardized curative effect evaluation basis for a clinical test for exploring a TACE-immunotherapy-anti-angiogenesis combined scheme.

The invention belongs to the technical field of biomedical detection, and particularly discloses a nucleic acid aptamer for specifically recognizing serum alpha fetoprotein and application of the nucleic acid aptamer. The nucleotide sequence of the nucleic acid aptamer comprises a sequence as shown in SEQ ID No.1, or has more than 90% of homology with the sequence as shown in SEQ ID No.1, or one or more nucleotides are deleted or added in the sequence as shown in SEQ ID No.1. The nucleic acid aptamer can realize specific efficient recognition of AFP protein, also shows extremely high selectivity in a complex serum sample environment, eliminates non-specific adsorption interference of homologous protein and other serum interference protein, greatly reduces the false positive rate, and improves the accuracy and specificity of clinical detection. And the material constructed by directionally functionalizing the aptamer on the surface of the magnetic nano-carrier has rapid magnetic response performance, separation and enrichment of target protein can be realized within seconds, and the clinical diagnosis time is greatly shortened.

A clinical decision support device, comprising: a parameter acquisition module, configured to acquire measured values for markers in a biomarker combination of a subject, wherein the biomarker combination at least comprises an alpha fetoprotein, an abnormal prothrombin, γ-glutamyltransferase, and an albumin; a risk assessment module, configured to input the measured values for the markers in the biomarker combination into a calculation model to obtain an output of the calculation model as a liver cancer risk prediction result of the subject; and an output module, configured to output the liver cancer risk prediction result of the subject. Also disclosed are a sample analysis system and a method for assessing a liver cancer risk of a subject, capable of better assessing a liver cancer risk of a subject.

The invention provides a living cell surface double-tumor marker in-situ detection method based on a closed bipolar electrode (cBPE) array and an electrochemiluminescence (ECL) technology. The living cell surface double-tumor marker in-situ detection method is used for synchronously quantifying carcino-embryonic antigen (CEA) and alpha-fetoprotein (AFP). According to the system, the high specific surface area, the ordered porous structure and the rich surface amino active sites of a covalent organic framework (COF) material are utilized, and the excellent conductivity and biocompatibility of gold nanoparticles (Au NPs) are combined, so that the bifunctional signal probe COF (at) Au (at) MBApt is constructed. The probe can simultaneously load a large number of signal molecule methylene blue (MB) and is coupled with a targeting aptamer (Apt), so that high-capacity labeling and specific recognition of a target marker are realized.

The application relates to a preparation method and application of a ternary heterojunction composite photoelectrochemical immunosensor, and belongs to the technical field of photoelectrochemical biosensors, and particularly relates to a preparation method and application of a photoelectrochemical immunosensor for detecting alpha-fetoprotein by adopting a BiPO4 / BiOBr / CdS composite material. The method is characterized in that a ternary heterojunction is assembled on an FTO modified electrode to fix a capture antibody, and the accurate determination of alpha-fetoprotein is realized through a photocurrent signal response. The BiPO4 / BiOBr heterojunction expands the forbidden band width and expands the light absorption range; due to the sensitization of CDs, the absorption of visible light is enhanced, so that the photocurrent signal is increased. The method has the advantages of good stability, strong specificity, high sensitivity, good reproducibility and the like, is good for the rapid detection of alpha-fetoprotein, solves the existing technical difficulties, and provides a feasible method for the detection of tumor markers.

The invention relates to the technical field of detection, in particular to a microfiltration device for alpha fetoprotein heteroplasmon detection, a limiting baffle ring is arranged at the top of a supporting head in a microfiltration head component, corresponding limiting is provided for placement of a filter membrane, and the filter membrane is in contact with the inner side wall of the limiting baffle ring, so that a gap is prevented from being generated, and the detection accuracy of alpha fetoprotein heteroplasmon detection is improved. The working efficiency of filtering and adsorbing the alpha fetoprotein heterogeneous is improved, and the positive effect is achieved on the accuracy of subsequent detection work; an auxiliary assembly is further arranged in the supporting head part, so that the filter membrane can be better taken out, and the phenomenon that the filter membrane is easily damaged when the filter membrane is clamped by tweezers from the middle part of the filter membrane is avoided; in addition, an auxiliary pressing ring in the arranged volume cup assembly also has an extrusion limiting effect on the filter membrane, namely the problem that the filter membrane shakes when liquid is poured in is avoided, and the working stability of the filter membrane is improved; and the method has positive significance in improving the detection and filtering work efficiency of the alpha fetoprotein variant.

The application belongs to the field of biosensors, and provides a construction method and application of an electrochemical biosensor for quantifying AFP-L3% (AFP-L3 / AFP), and the specific process is as follows: Au@UiO-66 nanocomposites are obtained by using a hydrothermal method and an immersion reduction method, TCEP can open S-S in alpha-fetoprotein to obtain sulfydryl (-SH) and connect to Au@UiO-66, in-situ synthesis of AFP aptamer-copper clusters (Apt-CuNCs) is carried out by using DNA as a template, Apt-CuNCs are used to recognize total AFP, the content of total AFP is determined by using the generated Cu electrochemical signal, then, the Apt-CuNCs are subjected to enzymatic cleavage and stripping by using exonuclease I, alpha-fetoprotein heterogeneity (AFP-L3) is labeled by using lentil agglutinin (LCA) functionalized silver nanoparticles LCA@AgNPs, the content of AFP-L3 is determined by using the generated Ag electrochemical signal, and AFP-L3% can be calculated by combining the data of the two, and the electrochemical biosensor constructed by the method can be used for determining AFP-L3% in human serum.

A system for generating a hepatocellular carcinoma (HCC) report for a subject based on blood-based molecular profiling is provided. The system includes a sample preparation module configured to process a blood sample by isolating both plasma and serum fractions. A nucleic acid extraction module extracts a microRNA (miRNA) profile from the plasma fraction, and a real-time PCR module detects and quantifies the expression levels of a predefined panel of miRNAs, including miR-361-5p, miR-130a-3p, miR-27a-3p, miR-30d-5p, and miR-193a-5p. The expression levels of the predefined panel of miRNAs are used by a trained machine learning classifier to generate a HCC risk classification categorizing the subject into one of HCC risk levels. An alpha-fetoprotein (AFP) level detected and quantified from the serum fraction may also be used in combination with the miRNA expression levels in the HCC risk classification for enhanced prediction accuracy.

The invention belongs to the technical field of alpha fetoprotein visual quantitative analysis, and particularly relates to a visual quantitative analysis method for alpha fetoprotein in saliva, a double-recognition multiple-quenching molecular imprinting and electrochemical luminescence microscope is constructed, and MI-ECLM takes self-developed SECLM as a signal output device and comprises a molecular imprinting polymer and a double-mechanism quencher; preparing a saliva sample and performing pretreatment; the pretreated saliva sample is placed on an MI-ECLM sensor, and an optical image is obtained through electrochemical luminescence imaging; and analyzing the optical image to realize visual quantitative detection of alpha fetoprotein in saliva.

The invention discloses an intelligent prediction system and method for early recurrence risk after liver cancer thermal ablation, and aims to solve the technical problem that prediction is not timely and inaccurate due to the fact that an existing prediction model ignores intraoperative dynamic information. According to the method, dynamic time sequence data such as tissue impedance and power in the thermal ablation process are collected in real time, and preoperative static data such as tumor size and alpha fetoprotein level are combined, so that a double-branch fusion prediction model is constructed. The model comprises a time sequence processing branch used for learning dynamic data time dependence and a static processing branch used for extracting static data features. By fusing the features of the two branches, the model can output a probability value representing the postoperative early recurrence risk. According to the method and the system, instant accurate risk stratification after operation is realized, and further, intraoperative intervention can be guided through real-time feedback, so that the early recurrence risk is actively reduced, and the prognosis of a patient is improved.

The invention discloses a method for detecting early hepatocellular carcinoma and a reagent set used by the method. The detection method comprises the following steps: performing biomarker identification of a group of methylated genes with difference in a computing system; performing, in a computing system, a quantitative measurement of the degree of methylation from the selected plurality of biomarkers in the group using a quantitative methylation-specific polymerase chain reaction; executing a formula calculation in the calculation system according to the methylation degree of the selected biomarker to obtain an M score of the selected biomarker; and performing a risk level assessment of hepatocellular carcinoma using the resulting M fraction or a combination of M fraction and serum alpha fetoprotein in a computing system.

The invention relates to the technical field of medical imaging omics analysis, and discloses an early-stage liver cancer postoperative recurrence prediction model and method based on imaging omics phenotypes, and the method comprises the following steps: data collection and preprocessing, feature screening and standardization, model construction, model verification and risk layering. The data acquisition and preprocessing is to obtain preoperative enhanced CT image data and clinical information of an early-stage hepatocellular carcinoma (HCC) patient meeting the agralan standard, and the clinical information comprises serum alpha fetoprotein (AFP) level and tumor number. According to the image omics phenotype-based early liver cancer postoperative recurrence prediction model and method, pre-operation and post-operation dual models are constructed by integrating pre-operation enhanced CT image omics characteristics (including first-order statistics, texture and wavelet characteristics), clinical parameters (such as serum alpha fetoprotein and tumor number) and post-operation pathological variables (such as microvascular invasion and satellite nodules).

This invention provides a nanocomposite material, its preparation method, and its application in a sandwich-structured enhanced immunosensor, belonging to the field of biosensor technology. This invention synthesizes a Ru@SiO2-NH2-Au nanocomposite material using a chemical oxidation method, constructs a Fe3O4@SiO2-NH2 composite carrier as a sensing platform, and successfully achieves ultrasensitive ECL immunosensor detection. The separation and enrichment of Fe3O4 during the sensing process improves detection efficiency. The -NH2 functional groups modified on the SiO2 surface provide active sites for the immobilization of the nanocomposite material and the specific recognition and binding of alpha-fetoprotein (AFP), achieving a highly efficient "carrier-functional material-target biomarker" interaction. This ECL immunosensor can detect AFP with high sensitivity, exhibiting a linear relationship within the range of 97.0% to 103.6%, with a detection limit of 1.28 × 10⁻⁶. ‑13 mg·mL ‑1 This provides a valuable reference for the future development of other AFP sensors.

This invention relates to the field of biodetection technology, and discloses a reagent composition, kit, and uses for liver cancer detection. The reagent composition provided by this invention includes a detection... FAM109B Gene, RIMS2 Gene, SNX31 Gene, FAR1 Genes and FLJ26850 The combination of primers and probes for gene methylation status enables the detection of methylation status of specific target sequences in the aforementioned liver cancer characteristic genes, achieving high sensitivity and specificity for liver cancer detection. The reagent composition of this invention allows for non-invasive liver cancer screening, and compared to conventional liver ultrasound and alpha-fetoprotein (AFP) testing, it significantly improves detection sensitivity, increases the accuracy of early liver cancer screening, and substantially reduces the rates of misdiagnosis and missed diagnosis.

The present invention relates to a composition for diagnosing, detecting, or monitoring a liver cancer disease, comprising nucleic acid affinity ligands and / or peptide affinity ligands for a group of biomarkers comprising at least Prolactin, Alpha Fetoprotein (AFP) and Interleukin-6 (IL-6) and, optionally, further comprising one or more of Squamous Cell Carcinoma Antigen (SCC), Metallopeptidase Inhibitor 1 (TIMP-1) and CYFRA 21-1. The present invention further envisages corresponding methods for diagnosing, detecting or monitoring a cancer disease in a subject, as well as a computer-implemented method for the analysis of a sample of a subject, a computer-implemented method for providing a trained machine learning model, the use of affinity ligands for detecting, diagnosing, or monitoring a liver cancer disease, in particular early forms of liver cancer.

The invention belongs to the technical field of liver disease diagnosis, and particularly relates to a biomarker for auxiliary diagnosis of liver diseases and application, the biomarker comprises serum phosphatidylcholine, and further comprises any one or two of alpha fetoprotein and chitosanase 3-like protein 1. As a newly discovered liver disease diagnosis index, the PC provided by the invention has the highest predictive ability in hepatitis and higher predictive ability in liver cirrhosis and liver cancer, can improve the predictive ability of other indexes on liver diseases, and has very high clinical value.

The present invention relates to in vitro diagnostic reagents, and in particular to a composition for determining alpha-fetoprotein heterogeneities and its application. The composition comprises a first reagent group for capturing alpha-fetoprotein heterogeneities and a second reagent group for separating and determining alpha-fetoprotein heterogeneities in the same reaction system; the first reagent group comprises a lectin magnetic bead reagent and a sample diluent; the second reagent group comprises an AFP capture magnetic bead reagent, a signal-labeled AFP detection antibody reagent, and an eluent; or the second reagent group comprises a streptavidin magnetic bead reagent, a biotin-labeled AFP capture antibody reagent, a signal-labeled AFP detection antibody reagent, and an eluent; or, the first reagent group comprises a lectin magnetic bead reagent and a streptavidin magnetic bead reagent; the second reagent group comprises a biotin-labeled AFP capture antibody reagent, a signal-labeled AFP detection antibody reagent, and an eluent. The composition has strong specificity, high sensitivity, and strong instrument versatility, and can greatly improve the detection efficiency of AFP-L3.

The invention relates to the technical field of detection, in particular to a microfiltration device for alpha fetoprotein heteroplasmon detection, a limiting baffle ring is arranged at the top of a supporting head in a microfiltration head component, corresponding limiting is provided for placement of a filter membrane, and the filter membrane is in contact with the inner side wall of the limiting baffle ring, so that a gap is prevented from being generated, and the detection accuracy of alpha fetoprotein heteroplasmon detection is improved. The working efficiency of filtering and adsorbing the alpha fetoprotein heterogeneous is improved, and the positive effect is achieved on the accuracy of subsequent detection work; an auxiliary assembly is further arranged in the supporting head part, so that the filter membrane can be better taken out, and the phenomenon that the filter membrane is easily damaged when the filter membrane is clamped by tweezers from the middle part of the filter membrane is avoided; in addition, an auxiliary pressing ring in the arranged volume cup assembly also has an extrusion limiting effect on the filter membrane, namely the problem that the filter membrane shakes when liquid is poured in is avoided, and the working stability of the filter membrane is improved; and the method has positive significance in improving the detection and filtering work efficiency of the alpha fetoprotein variant.

The present invention relates to a specific TCR molecule, TCR-T cell, preparation and application targeting the complex of alpha-fetoprotein antigen peptide and HLA-A24 of liver cancer cells, belonging to the field of genetic engineering and immunotechnology. The specific TCR molecule of the present invention can specifically bind to the complex of alpha-fetoprotein and HLA-A24, and can specifically kill liver cancer tumor cells expressing the complex. This study combines single-cell transcriptome sequencing analysis of hepatocellular carcinoma with TCR immune group analysis, MHC phenotypic analysis, antigen peptide and MHC affinity, and TCR and antigen peptide and MHC binding analysis to perform deep machine learning combined with multi-omics algorithms. The TCR11-T of the present invention has high lethality to HLA-A24 (+) tumor cell lines with high expression of alpha-fetoprotein.

The invention discloses a preparation method of an alpha fetoprotein quantitative detection kit, which is characterized by comprising the following steps: step 1, coating MM15 monoclonal antibodies under optimized conditions, and grouping the MM15 monoclonal antibodies; step 2, respectively adding alpha fetoprotein antigens with the concentrations of 625 ng / mL, 312.5 ng / mL, 156.3 ng / mL, 78.1 ng / mL, 39.0 ng / mL, 19.5 ng / mL, 9.8 ng / mL, 4.9 ng / mL, 2.45 ng / mL and 1.22 ng / mL; according to the preparation and use method of the alpha fetoprotein quantitative detection kit, a targeted AFP self-assembly affinity polypeptide dimer is constructed in the method, and a plurality of affinity polypeptide molecules are assembled into particles with larger molecular weight, so that on one hand, the purpose of amplifying signals in sandwich ELISA is achieved; and on the other hand, the self-assembled affinity polypeptide dimer is expressed in the form of an active inclusion body, the step of affinity chromatography is omitted during purification, and the protein with higher purity can be obtained through centrifugation, so that the technical requirements are relatively low, and more cost is saved.

The present invention provides a fluorescent reagent for detecting tumor markers, a preparation method thereof, a method for constructing a fluorescent sensor array sensing unit, and an application thereof. The fluorescent reagent includes a probe composed of one or more carbon dots including at least three sites of amino, carboxyl, hydroxyl or sulfhydryl groups, or a probe constructed by combining carbon dots with IRMOF‑3. Its preparation method includes a hydrothermal method, a microwave method or a method of combining carbon dots with IRMOF‑3. The fluorescent reagent is used to construct a fluorescent sensor array sensing unit and is used to quantitatively detect the concentration of tumor markers in the blood of unknown samples, and to verify whether it exceeds a threshold value to infer whether the patient is a tumor patient. The actual blood sample consumption is low, the operation is simple, and the detection efficiency is greatly improved. The present invention can simultaneously distinguish multiple tumor markers, such as carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 15‑3 (CA15‑3), alpha-fetoprotein (AFP), etc., and the required sample amount is small and the detection time is short.

The invention discloses construction and application of a bifunctional biosensor based on coordination induced enhancement and interface antifouling, and belongs to the technical fields of light / electrochemistry, biochemical analysis and nano science. According to the invention, tris (4, 4 '-dicarboxylic acid-2, 2'-dipyridyl) ruthenium is used as a ligand, and Zn / Ru-MOF with a coordination induction enhancement effect is prepared and is used as a luminous body. Due to effective aggregation of the ligand and energy transfer from Zn < 2 + > to the ligand, Zn / Ru-MOF has high ECL efficiency. Besides, Zn / Ru-MOF is modified with 3-aminopropyl dimethylamine zwitterions to serve as a sensing substrate, so that interface adsorption of interfering substances is resisted, and integration of self-enhanced luminescence and interface antifouling is realized. Based on pairing of a complementary chain and an aptamer chain, a significant "signal-off" is achieved through resonance energy transfer. The quenching probe is released according to the competitive mechanism of the target, resulting in signal recovery. Based on this, the constructed biosensor shows a low detection limit, and shows a huge application potential in clinical monitoring of alpha fetoprotein in a complex serum medium.

The invention provides a system for detecting hepatocellular carcinoma micro-RNA (Ribonucleic Acid) based on blood molecular spectrum analysis. The system includes a sample preparation module for processing a blood sample of a subject and separating a plasma portion and a serum portion therefrom. And the nucleic acid extraction module is used for extracting the microRNA expression spectrum from the plasma part. The real-time polymerase chain reaction module is used for detecting and quantifying the expression quantity of the micro RNA group in the micro RNA expression spectrum, and the real-time polymerase chain reaction module comprises miR-361-5p, miR-130a-3p, miR-27a-3p, miR-30d-5p and miR-193a-5p. Processing by a trained classifier according to the quantitative result to generate a hepatocellular carcinoma risk classification result so as to grade the subjects according to the hepatocellular carcinoma risk; and the trained classifier processing can be further incorporated into a result generated by combining the alpha fetoprotein expression quantity detected and quantified from the serum part with the expression quantity of the microRNA group, so that the accuracy is improved.

The present application relates to a kind of preparation method of redox probe based on metal organic framework derived nanosheet and its product and application, belong to the technical field of preparation of redox probe.The present application is mainly to form super-thin metal organic framework material by self-assembly of metal ion (Cu 2+ Or Co 2+ ) and organic ligand, continue to react with ascorbic acid (AA), chloroauric acid (HAuCl4) to obtain metal-UMOFNs@Au NPs, then mixed with alpha-fetoprotein antibody (anti-AFP), carcinoembryonic antibody (anti-CEA) and glucose oxidase (GOD) after incubation to obtain redox probe (metal-UMOFNs@Au NP-Ab2-GOD).In addition, the redox probe prepared by the present application can be used to prepare sandwich-type electrochemical immunosensor capable of simultaneously detecting CEA and / or AFP, and the immunosensor has higher sensitivity, good selectivity and stability.

The present invention relates to a method for providing information necessary for the diagnosis of liver cancer by measuring the percentage of fucosylated AFP (AFP-Fuc%). In the present invention, AFP present at a low concentration in serum is quantified with excellent sensitivity by performing direct mass spectrometry on total fucosylated AFP without glycan removal or the use of antibodies or lectins that recognize fucosylation sites, and hepatocellular carcinoma is detected with significantly improved accuracy compared to conventional GALAD scores using Lens culinaris agglutinin-reactive fraction (AFP-L3) as a marker. In particular, the present invention can be effectively used to establish treatment strategies early and improve patient survival rates by distinguishing early hepatocellular carcinoma from common non-tumor liver diseases with high reliability.

This invention discloses an ultrasensitive and rapid sensor for detecting alpha-fetoprotein (AFP), constructed based on a sandwich immunoassay structure and the electrochemiluminescence resonance energy transfer (ECL-RET) principle. The advantages of this invention compared to existing technologies are: high sensitivity and ultra-low detection limit: This invention innovatively uses MIL-NH2-RuMOF@Pt as an energy donor, whose MOF structure can load a large amount of Ru(bpy)3. 2+ The luminescent molecule provides a strong and stable initial ECL signal; ZnO@PDA acts as the acceptor, with its absorption spectrum highly overlapping with the donor emission spectrum, and PDA modification improves biocompatibility and coupling efficiency. The highly efficient RET pair formed by these two molecules, combined with the sandwich immunoamplification effect, achieves efficient signal quenching, resulting in a detection limit as low as 1.1 × 10⁻⁶. ‑ 14 mg·mL⁻¹; wide linear range; excellent specificity and accuracy; good stability and repeatability; broad application prospects.

This application relates to a clinical decision support device, comprising: a parameter acquisition module configured to acquire the measured values ​​of each biomarker in a biomarker combination of a subject, wherein the biomarker combination includes at least alpha-fetoprotein, abnormal prothrombin, gamma-glutamyl transferase, and albumin; a risk assessment module configured to input the measured values ​​of each biomarker in the biomarker combination into a computational model, and obtain the output of the computational model as a liver cancer risk prediction result for the subject; and an output module configured to output the liver cancer risk prediction result for the subject. This application also relates to a sample analysis system and a method for assessing the liver cancer risk of a subject. This application enables improved assessment of the liver cancer risk of a subject.